Hormonal
Testosterone replacement therapy (TRT) restores serum testosterone to normal ranges, thereby improving mood, energy, sexual function, lean body mass, erythropoiesis, and bone mineral density in hypogonadal men.
If you have clinically low testosterone and symptoms like low energy, low libido, or loss of muscle mass, TRT can restore your levels to normal and improve these symptoms. There are many forms of treatment (gels, patches, injections, buccal tablets) to suit your preference. Regular monitoring of your prostate and blood counts is essential to ensure safety.
Using testosterone replacement therapy to restore testosterone to within the normal range for young adult men [>= 10-35 nmol/l (2.88-10.00 ng/ml)] can improve many of the effects of hypogonadism. Most importantly, these include beneficial effects on mood and energy levels, thereby improving patients' sense of well-being, sexual function (especially libido, but also erectile function if this is related to hypogonadism), lean body mass, erythropoiesis (improving anaemia if present and due to hypogonadism) and bone mineral density (BMD).
Why this rating
The paper cites multiple studies (Snyder, Kenny, Nieschlag) showing consistent benefits, though it notes some variability in lipid responses.
Source
Testosterone replacement therapy: current trends and future directions
Eberhard Nieschlag et al. · Human Reproduction Update · 2004
DOI 10.1093/humupd/dmh035
More from this paper
- Testosterone replacement therapy improves bone mineral density (BMD) and reduces fracture risk in hypogonadal men, with effects mediated by both androgen and estrogen receptors.Good
- Testosterone replacement therapy may have beneficial effects on cardiovascular health in men with coronary artery disease or chronic heart failure, improving exercise tolerance and vascular reactivity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →